PHARMACEUTICAL SOLUTIONS

The market is flooded with a plethora of nutraceutical products offered by countless players giving rise to cut-throat competition. This industry is essentially consumer-driven and thus consumers play an important role choose the fate of those products. The expectations of health conscious consumers are many and their number is consistently on the increase .   Sustainability Is En Vogue “Sustainability” has been the buzzword in most industries for quite a while now. it's going to mean products developed using naturally-derived ingredients or minimally processed products. it's going to even ask products manufactured using fewer and known or recognizable ingredients. Currently there's no consensus on the usage of this term neither is its scope completely defined. However, as far as consumer choices are concerned, a clear shift towards vegetarianism has been observed. Animal-based products are now a strict no-no. Today consumers search for plant-based, natural ingredient

  Over the  previous couple of  decades, vaccine delivery has evolved substantially, shifting from  the utilization  of conventional inactive or live attenuated pathogen to more advanced recombinant substances with adjuvants (the boosting agents that enhance immune stimulation). Polymers as adjuvants have augmented the formulation and delivery of vaccines,  resulting in  modern vaccination approaches through oral and nasal pathways.  the utilization  of polymeric substances in vaccines is gaining popularity, primarily  due to  their ability  to enhance  vaccine efficacy and achieve desired immune responses through targeted delivery. Diverse approaches for vaccine delivery that are currently available  are  listed in Table 1. Table 1: Different vaccine delivery techniques Technique   Example   Adjuvant  Poly lactic co-Glycolic Acid (PLGA), Alum, Liposome  Oral vaccine  Enteric-coated formulation  DNA vaccine

The COVID-19 crisis has taken  the planet  by storm and paralysed every industry like never before. This unforeseen situation has raised many  inquiries to  the pharma industry, making them  believe  their readiness to tackle such challenges  within the  future.  is that the  pharma capable of running continuous production  during a  critical time like these? How equipped are they  to take care of  or maybe  increase the output without compromising quality? How can the industry minimise human involvement in routine manufacturing operations? It’s about time the pharma industry  cares  AI  (AI).  the importance  of AI was never realised more before than now! Big pharma has already started adopting AI for drug design and development. AI  is additionally  getting used  in specific patient  education schemes  and for personalised medicines to facilitate treatment. However, there are still many areas in pharma where the uses of AI are yet to be explored. Understanding AI AI  are often 

  Incidents of substandard or fraudulent pharmaceutical products  still  increase through what are assumed to be legitimate supply chains  round the  world. A recently released report by Organization for Economic Cooperation and Development (OECD)  and therefore the  european union   property  Office (EUIPO) estimates that international  trade  counterfeit pharmaceuticals reached USD 4.4 billion in 2016. These counterfeit medicines are believed to origin mostly in developing countries  which will  penetrate supply chains and make their  thanks to  anywhere  within the  world. This leaves regulators and distributors  during a  frenzy who struggle to locate substandard products that have entered the system. These potentially harmful products pose serious risk to the health of  many  patients who buy and consume these medicines believing that  they're  safe and effective. To address  a number of  these supply chain challenges, the pharmaceutical industry  is popping  to blockchain tec

  Recent advancements in biologics have unleashed tremendous opportunities in addressing unmet medical needs taking healthcare to new heights. Biologics have shown promising  leads to  the treatment of debilitating conditions  like  diabetes, cancer, autoimmune diseases that affect millions worldwide. The success biologics  are often  attributed to their high specificity and enhanced therapeutic potential over conventional small molecules. It should come as no surprise then  that almost  80% of the novel drugs approved by the US FDA in 2020 constituted of biologics. Currently,  quite  800 peptide drugs are  within the  pipeline and around 197 peptide-based drugs  are  commercialised.  the worldwide  biologics market stood at an estimated USD 269,152 million in 2019 and  is predicted  to grow at a CAGR of 14.7%  to succeed in  up to USD 464,604 million by 2023. Asia-Pacific  especially  accounted for  the most important  market with a whopping 53.1% share  of worldwide  biologics in 201